604 related articles for article (PubMed ID: 12495904)
21. Identification of RUNX1/AML1 as a classical tumor suppressor gene.
Silva FP; Morolli B; Storlazzi CT; Anelli L; Wessels H; Bezrookove V; Kluin-Nelemans HC; Giphart-Gassler M
Oncogene; 2003 Jan; 22(4):538-47. PubMed ID: 12555067
[TBL] [Abstract][Full Text] [Related]
22. Upstream and downstream targets of RUNX proteins.
Otto F; Lübbert M; Stock M
J Cell Biochem; 2003 May; 89(1):9-18. PubMed ID: 12682904
[TBL] [Abstract][Full Text] [Related]
23. RUNX1 translocations in malignant hemopathies.
De Braekeleer E; Férec C; De Braekeleer M
Anticancer Res; 2009 Apr; 29(4):1031-7. PubMed ID: 19414342
[TBL] [Abstract][Full Text] [Related]
24. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
Miller JD; Stacy T; Liu PP; Speck NA
Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
[TBL] [Abstract][Full Text] [Related]
25. Expression of AML/Runx and ETO/MTG family members during hematopoietic differentiation of embryonic stem cells.
Okumura AJ; Peterson LF; Lo MC; Zhang DE
Exp Hematol; 2007 Jun; 35(6):978-88. PubMed ID: 17533052
[TBL] [Abstract][Full Text] [Related]
26. A 5' untranslated region containing the IRES element in the Runx1 gene is required for angiogenesis, hematopoiesis and leukemogenesis in a knock-in mouse model.
Nagamachi A; Htun PW; Ma F; Miyazaki K; Yamasaki N; Kanno M; Inaba T; Honda Z; Okuda T; Oda H; Tsuji K; Honda H
Dev Biol; 2010 Sep; 345(2):226-36. PubMed ID: 20647008
[TBL] [Abstract][Full Text] [Related]
27. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
28. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
[TBL] [Abstract][Full Text] [Related]
29. The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp.
Bravo J; Li Z; Speck NA; Warren AJ
Nat Struct Biol; 2001 Apr; 8(4):371-8. PubMed ID: 11276260
[TBL] [Abstract][Full Text] [Related]
30. Alterations of the AML1 transcription factor in human leukemia.
Downing JR; Higuchi M; Lenny N; Yeoh AE
Semin Cell Dev Biol; 2000 Oct; 11(5):347-60. PubMed ID: 11105899
[TBL] [Abstract][Full Text] [Related]
31. [Loss-of-function of AML1/PEBP2 alpha B and leukemogenesis].
Osato M; Ito Y; Asou N
Tanpakushitsu Kakusan Koso; 2000 Jan; 45(1):40-7. PubMed ID: 10643334
[No Abstract] [Full Text] [Related]
32. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.
Wotton S; Stewart M; Blyth K; Vaillant F; Kilbey A; Neil JC; Cameron ER
Cancer Res; 2002 Dec; 62(24):7181-5. PubMed ID: 12499254
[TBL] [Abstract][Full Text] [Related]
33. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
[TBL] [Abstract][Full Text] [Related]
34. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
35. AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia.
Barton K; Nucifora G
Bioessays; 2000 Mar; 22(3):214-8. PubMed ID: 10684580
[TBL] [Abstract][Full Text] [Related]
36. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
37. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
38. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.
Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A
J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049
[TBL] [Abstract][Full Text] [Related]
39. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
[TBL] [Abstract][Full Text] [Related]
40. Overexpression or knock-down of runt-related transcription factor 1 affects BCR-ABL-induced proliferation and migration in vitro and leukemogenesis in vivo in mice.
Yang LJ; Yu WD; DU JB; Chao S; Chen MX; Zhao HH; Guo JZ
Chin Med J (Engl); 2009 Feb; 122(3):331-7. PubMed ID: 19236814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
